ArticleNature communications2021
Chromatin accessibility of circulating CD8
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Chromatin accessibility of circulating CD8⁺ T cells differentiates disease severity in IgA nephropathy.Scientific reports · 2025Article
- Role of circulating tumor DNA methylation in gastric cancer initiation and progression: A comprehensive review.World journal of gastrointestinal oncology · 2025Review
- Role of lysine-specific demethylase 1 in immunotherapy of gastric cancer: An update.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024Article
- Three-dimensional isotropic imaging of live suspension cells enabled by droplet microvortices.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- CRIF1 deficiency induces FOXP3Science advances · 2024Article
- Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction.Biomarker research · 2023Review
- OCRFinder: a noise-tolerance machine learning method for accurately estimating open chromatin regions.Frontiers in genetics · 2023Article
- Application of ATAC-seq in tumor-specific T cell exhaustion.Cancer gene therapy · 2023Review
- Research progress on the immune microenvironment and immunotherapy in gastric cancer.Frontiers in immunology · 2023Review
- Article
- Stress-Mediated Attenuation of Translation Undermines T-cell Activity in Cancer.Cancer research · 2022Article
- Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study.Annals of surgical oncology · 2022Review
- Liquid biopsy in gastric cancer: predictive and prognostic biomarkers.Cell death & disease · 2022Review
- Gastric cancer and genomics: review of literature.Journal of gastroenterology · 2022Review
- Chromatin Dynamics in Digestive System Cancer: Commander and Regulator.Frontiers in oncology · 2022Review
- Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer.Frontiers in immunology · 2022Review
- Lack of CD8Science immunology · 2021Article
- ELK4-mediated lncRNA SNHG22 promotes gastric cancer progression through interacting with EZH2 and regulating miR-200c-3p/Notch1 axis.Cell death & disease · 2021Article
- The cross talk between gastric cancer stem cells and the immune microenvironment: a tumor-promoting factor.Stem cell research & therapy · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although tumor genomic profiling has identified small subsets of gastric cancer (GC) patients with clinical benefit from anti-PD-1 treatment, not all responses can be explained by tumor sequencing alone. We investigate epigenetic elements responsible for the differential response to anti-PD-1 therapy by quantitatively assessing the genome-wide chromatin accessibility of circulating CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.